Ascendis Pharma (NASDAQ: ASND) received FDA orphan status for its treatment of Achondroplasia. Generic Name: C-type natriuretic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

Ascendis Pharma (ASND) Reports Positive Top-Line Results from Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency, Demonstrating Superiority on Primary EndpointMarch 4, 2019 6:35 AM